Abstract
Background
Although oncogenic human papillomavirus (HPV) infections have been established as the necessary cause of cervical cancer, most HPV infections are transient and rarely progress to squamous cervical lesions. The activity of HPV is tightly associated with epithelial cell differentiation; therefore regulators of differentiation, such as retinoic acid, have been considered targets for the prevention of HPV-associated squamous intraepithelial lesion (SIL) development.
Purpose
The purpose of this study was to determine the association between circulating retinoic acid (RA) and early events in cervical carcinogenesis, specifically type-specific HPV clearance and SIL detection.
Methods
Archived blood samples from 643 women participating in the Ludwig-McGill Cohort in São Paulo, Brazil were analyzed by high-pressure liquid chromatography for three RA isomers (all-trans, 13-cis, and 9-cis RA). A type-specific HPV clearance event was defined as two consecutive visits negative for that HPV type during follow-up for the 364 HPV positive women. Among the 643 women in this analysis, 78 were diagnosed with incident SIL.
Results
The probability of clearing an oncogenic HPV infection was not significantly different across RA isomer quartiles. There was a suggestion that increasing all-trans RA increased rate of non-oncogenic HPV clearance (p-trend=0.05). There was no association observed between serum RA levels and incident SIL.
Conclusions
Our results suggest that elevated circulating RA isomer levels do not increase rates of HPV clearance or reduce risk of incident SIL. The role of RA in the inhibition of HPV induced carcinogenesis, as demonstrated in vitro, lacks confirmatory evidence within epidemiologic studies among women.
Keywords: Human Papillomavirus, clearance, retinoic acid, retinoids, squamous intraepithelial lesions, dysplasia, cervix, cervical cancer
Introduction
Epidemiologic research has shown that infection with human papillomavirus (HPV) is a cause of cervical cancer (1). Women infected with HPV are more likely to develop cervical abnormalities such as squamous intraepithelial lesions (SIL). Although HPV is the causal agent of cervical cancer, not all HPV infections lead to dysplasia or cervical cancer. Early events upon HPV acquisition are critical to the establishment of an HPV infection that evades the immune system, persists over time, and leads to the development of cervical dysplasia and possibly cancer (2). Since the activity of HPV in cervical cells is tightly associated with epithelial cell differentiation (3) regulators of differentiation, such as retinoic acid (RA) (4), have been considered targets for the prevention of HPV persistence and SIL development (5).
RA is the biologically active form of vitamin A, which is obtained from the diet as retinol esters or as pro-vitamin A carotenoids (6). RA isomers (all-trans-RA, 9-cis-RA, and 13-cis-RA) have different biological activities. All-trans- and 9-cis-RA bind to nuclear retinoid receptors that regulate gene transcription (7). RA receptor binds to all-trans- and 9-cis-RA with equal affinity, whereas retinoid X receptor preferentially binds 9-cis-RA (8). In comparison, 13-cis-RA has no nuclear receptor and is considered an inert form of all-trans-RA (9). In vitro, RA is a potent inhibiter of HPV-16 immortalized cervical epithelial cells’ growth (10) and down regulates expression of HPV-16 E6 and E7 (11–14). In epidemiologic studies, RA precursors (vitamin A and pro-vitamin A carotenoids) have been inconsistently associated with a decreased risk of cervical neoplasia (15). Regression of cervical intraepithelial neoplasia (CIN) II following treatment with all-trans-RA has been reported (16); however, subsequent chemoprevention trials utilizing all-trans-RA, 13-cis-RA or RA-derivatives did not observe significant differences between treatment and placebo groups for CIN II or CIN III regression (17–21). There has been one published report suggesting a decrease in serum all-trans-RA with increasing cervical lesion severity which did not take into consideration HPV infection(22). Overall, the association between RA and HPV-associated neoplasia remains undetermined
Until recently, epidemiologic studies did not have access to a sufficiently sensitive laboratory assay for the measurement of circulating RA, which occurs at very low concentrations. We demonstrated the feasibility of measuring endogenous RA, identified low within-person variability of total RA and individual isomers (all-trans, 13-cis-, and 9-cis-RA) and established that serum RA measures correlate with RA precursors, both circulating and dietary (23). Serum RA appears to be a reliable measure of dietary RA for use in larger scale epidemiologic studies. Using this novel measure of circulating RA, we evaluated if serum RA levels were associated with early events in cervical carcinogenesis, specifically type-specific HPV clearance and risk of incident SIL. This study of 643 women was part of a larger study investigating antioxidant nutrient and HPV outcomes nested within the Ludwig-McGill Cohort in São Paulo, Brazil (24, 25).
MATERIALS AND METHODS
Participants of the Ludwig-McGill Cohort Study were recruited from patients who attended a comprehensive maternal and child health maintenance program between 1993–1997 that served low-income families in São Paulo, Brazil (26). Cohort participants were followed every 4-months during the first year and twice yearly thereafter for over nine years. During each study visit, participants underwent a gynecological exam, provided a blood sample and were interviewed using a structured questionnaire that was specific for each visit (26). Each study participant signed an approved informed consent document. The institutional review boards and ethical committees of all institutions with which the authors are affiliated approved all study documents and procedures.
Cervical Cytology
During each participant visit, a sample of ecto- and endocervical cells were collected by use of an Accelon biosampler (Medscand, Inc., Hollywood, FL) for Pap cytology and HPV testing. Pap smears were prepared on a glass slide and fixed in 95% ethanol. The biosampler containing exfoliated cells was swirled in Tris-EDTA buffer (pH 7.4), delivered to the Ludwig Institute laboratory at 4°C, and then archived at −20°C until used for HPV testing. Pap smears were evaluated for cytological diagnosis according to the Bethesda system (negative for abnormality, atypical squamous or glandular cells of undetermined significance (ASCUS/AGUS), LSIL, HSIL, cancer, or inconclusive) (27).
HPV Genotyping
Cervical cells were treated with 100 µg/mL proteinase K for 3 hours at 55°C, followed by organic extraction and ethanol precipitation of DNA. HPV DNA was detected by polymerase chain reaction (PCR) amplification of a 450-bp segment in the L1 viral gene using MY09/11 consensus primers (28, 29), as previously reported (26). Each PCR included positive and negative controls and DNA quality was assessed using amplification of a 268-bp fragment of the β-globin gene. HPV typing was performed by dot-blot hybridization with individual oligo-nucleotide probes specific for 27 HPV genital types(30) (types 6/11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51–59, 66, 68, 73, 82, 83, and 84). The PCR amplification products were further tested by restriction fragment–length polymorphism (RFLP) analysis of the L1 fragment (31) to resolve ambiguous results from the dot-blot hybridization and to distinguish additional HPVs (32, 34, 44, 61, 62, 67, 69–72, and 89). All HPV analyses were performed at the Ludwig Institute for Cancer Research, São Paulo, Brazil.
Study Sample
Nested within the Ludwig-McGill Cohort, we identified a sample of 818 participants for an investigation of antioxidant nutrients and HPV persistence and risk of SIL (24, 25). Selection criteria for the antioxidant nutrient study included available HPV results from year 1 study visits, archived blood samples available and normal or ASCUS cervical cytology at enrollment. HPV positive women were frequency matched on age (±5-years) and enrollment date (±180 days) to HPV negative women during the same follow-up period. For the current study, valid serum RA results were available for 643 women where values were within ±3 SD of the mean RA. Among the 643 women, 364 were HPV positive and 277 HPV negative and 78 developed a low-grade SIL (LSIL) or high-grade SIL (HSIL) as the most severe cytological grade during follow-up (65 LSIL and 13 HSIL). Among women with an incident SIL lesion, 96% (75/ 78) tested positive for HPV at least once prior to or at the same visit as the lesion was detected.
Serum Sample Processing and Storage
All non-fasting blood samples (~10 ml) were collected by venipuncture into vacutainers by a trained nurse at the time of the clinic visit. The samples were centrifuged within 6–8 hours of collection. Aliquots (1 ml) of serum were stored in 1.8 ml Nunc cryovials at −20°C in a non-frost free freezer until shipped for analyses.
High-pressure liquid chromatography (HPLC) analysis of serum RA
RA analyses were conducted on 500 µl of serum from samples obtained at the first two visits (months 0 and 4), as previously reported (23) using a modification of a method initially reported by Horst et al. (32). All analytical procedures were performed under UV protected lights. Linear calibration curves were prepared consisting of three concentrations of RA isomers that spanned serum physiological levels. Quantification was performed by external standard calibration using peak area ratios. In-house quality control (QC) samples were analyzed at the beginning and end of each sample queue. The relative standard deviation of analytes in the QC samples ranged from 10–15%. QC samples were the basis of determining the quality and inclusion of results in the final analysis. For statistical purposes, samples with values below the detectable limit of the assay (0.3 ng/ml or 5 pmol/L) were assigned a value half way between zero and the lower limits of detection, which consisted of 32 (2.5%) all-trans-RA samples of the 1286 samples analyzed from the 643 women. No 9-cis- or 13-cis-RA samples were below the detectable limit. The mean RA level was calculated for each woman from the two measures and then categorized into quartiles based on the HPV positive group.
Statistical Analysis
For person-level analyses, women infected with single or multiple oncogenic HPV types (HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66)(33) and women infected with both oncogenic and non-oncogenic HPV types were categorized as having an oncogenic infection. Unclassified HPV types were excluded from the analysis of type-specific HPV clearance. Women infected with a single or multiple non-oncogenic types were categorized as having a non-oncogenic infection. Of the 643 women in this analysis, 248 women were classified as having oncogenic infection and 116 as having non-oncogenic infections. In infection-level analyses, women with multiple infections contributed multiple outcome events. Of the 755 HPV infections, 396 (52.5%) were oncogenic and 359 (47.5%) were non-oncogenic. HPV-16 was also evaluated as a separate outcome among 91 HPV-16 infections.
Time to HPV clearance for each type-specific HPV infection was measured as the time from the first visit positive for a specific HPV type until the first of two consecutively negative HPV tests (clearance event), or until the last visit if the participant remained positive throughout the study period (censored event). Two consecutively negative tests defined clearance to reduce the possibility of a false-negative test result (e.g. +,−, +), which occurred in 29 women (8% of HPV positive). HPV status was assumed to remain unchanged across single missing visits, but infections spanning 2 or more consecutive missing visits after the time of infection were excluded (n=2). HPV infections that became negative at a woman’s last study visit were censored. To ensure comparability of clearance assumptions for censored and noncensored infections, we added six months to person-time contributed by HPV infections present at a woman’s last study visit.
Multivariable Cox proportional hazards modeling was conducted to estimate hazard ratios (HR) and 95% confidence intervals (CI) of clearance events adjusted for potential confounders. For infection level analyses, multivariable Cox proportional hazards modeling was adjusted for clustered data. Mean RA level categorized into quartiles was included as a fixed covariate within the models. In the person-level analyses, women who developed an incident SIL (LSIL or HSIL) during follow-up (cases) were compared to women who did not develop LSIL or HSIL over the same time period (controls). Logistic regression was performed to estimate the magnitude of association (OR 95% CI) between RA isomers and incident SIL, controlling for HPV status or restricting to women that were HPV positive (data not shown).
All multivariable models evaluated factors that could potentially confound or mediate the associations with persistence of HPV infection, SIL and serum RA levels (23) including: age, race, income, education, marital status, smoking, oral contraceptive use, number of pregnancies, age at first sexual intercourse, and number of sexual partners (lifetime or last 5 years). Factors that altered the risk estimate by 10% were retained in the final model. In the infection-level analyses, adjustment factors previously associated with circulating RA and HPV were forced in the model. Tests for trends were performed by treating categorized RA variables as continuous in the final models. All statistical tests performed were two-sided and declared at the 5% significance level. Statistical analyses were performed with SAS® software, version 9.1.3 and Intercooled STATA (Stata, Release 9.0; Stata Corp., College Station, Tx).
RESULTS
The demographic and risk factor distributions for this sample of women from the Ludwig-McGill Cohort study have been previously published (23, 25). Women were between the ages of 18 and 57, with a median age of 32 years. The concentration of RA isomers in this sample is presented in Table 1. The median and range of the RA isomer were 1.455 ng/mL and 0.050–4.895 ng/mL for 13-cis-RA, 1.240 ng/mL and 0.0360–3.225 ng/mL for 9-cis-RA, and 0.715 ng/mL and 0.150–2.625 ng/mL for all-trans-RA (Table 1). RA isomer level did not differ between HPV negative and HPV positive women, nor did levels significantly differ between SIL cases and controls.
Table 1.
Circulating Retinoic Acid Concentrations, by HPV and SIL status*
| Retinoic Acid Isomers (ng/mL)† |
Total (n=643) |
HPV Negative Controls (n=274) |
Positive Controls (n=291) |
SIL Case (n=78) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | Range | Median | Range | Median | Range | Median | Range | |||||
| Total Retinoic Acid | 3.470 | 1.510, | 7.790 | 3.468 | 1.510, | 7.790 | 3.485 | 1.525, | 7.685 | 3.410 | 1.945, | 6.035 |
| cis-isomer | ||||||||||||
| 13-cis RA | 1.455 | 0.505, | 4.895 | 1.453 | 0.550, | 4.895 | 1.415 | 0.505, | 3.905 | 1.548 | 0.630, | 3.025 |
| 9-cis RA | 1.240 | 0.360, | 3.225 | 1.260 | 0.495, | 3.225 | 1.200 | 0.480, | 3.200 | 1.250 | 0.360, | 2.130 |
| All-trans-isomer | 0.715 | 0.150, | 2.625 | 0.715 | 0.230, | 2.165 | 0.7152 | 0.150, | 2.625 | 0.678 | 0.150, | 1.845 |
No statistically significant differences found across groups (HPV negative, HPV positive and SIL), as tested by the Kruskal-Wallis test for equality of populations
Limit of quantification (LOQ) was 0.30 ng/mL, values below LOQ were given value of 0.15 ng/mL
Table 2 presents the risk (HR) of type-specific HPV clearance among the 248 women positive for at least one oncogenic HPV type and the 116 women positive for non-oncogenic infection. The probability of clearing an oncogenic HPV infection was not significantly different across RA isomer quartiles. There was a significant trend of increased rate of non-oncogenic HPV clearance with increasing all-trans-RA (p=0.048); however, individual quartiles of all-trans RA were not significant. In the infection-level analyses, serum RA isomers were not associated with individual oncogenic HPV clearance (Supplemental Data Table 1). Among the 359 non-oncogenic HPV infections, women in the highest quartile of all-trans-RA were 1.55 (95% CI: 1.02–2.36; p-trend = 0.01) times more likely to clear a non-oncogenic HPV infection compared to women with the lowest levels (Supplemental Table 1). Consistent with the analysis that included prevalent and incident infections, no significant associations were observed when restricting analyses to incident HPV infections in both women-level and infection-level analyses (Supplemental Table 2 and 3). Clearance of HPV 16 was significantly less likely among women with total RA above the median (adjusted HR = 0.58; 95% CI 0.35–0.98) and marginally significant with 9-cis-RA level above the median (adjusted HR = 0.63; 95% CI 0.38–1.06) (Table 3). There were no significant associations observed between clearance of HPV 16 and 13-cis-RA and all-trans-RA.
Table 2.
Association between type-specific oncogenic and non-oncogenic HPV clearance and serum retinoic acid concentrations among 364 women: Women-level analyses
| Oncogenic HPV | Non-Oncogenic HPV | |||||||
|---|---|---|---|---|---|---|---|---|
| Nutrients (ng/mL) | No. Cleared / women-months* |
Crude | Adjusted† | No. Cleared / women-months* |
Crude | Adjusted‡ | ||
| HR | HR | (95% CI) | HR | HR | (95% CI) | |||
| Total Retinoic Acid | ||||||||
| Quartile 1 (≤ 2.86) | 50 / 783.18 | 1.00 | 1.00 | Referent | 23 / 270.82 | 1.00 | 1.00 | Referent |
| Quartile 2 (2.86 – 3.46) | 42 / 824.05 | 0.84 | 0.75 | (0.49, 1.14) | 27 / 344.08 | 0.85 | 0.71 | (0.36, 1.41) |
| Quartile 3 (3.47 – 4.11) | 47 / 688.23 | 1.09 | 1.02 | (0.67, 1.55) | 25 / 330.51 | 0.81 | 0.82 | (0.44, 1.50) |
| Quartile 4 (> 4.11) | 48 / 883.48 | 0.96 | 0.86 | (0.56, 1.32) | 24 / 247.89 | 1.01 | 1.28 | (0.66, 2.47) |
| p for trend | 0.765 | 0.392 | ||||||
| 13-cis RA | ||||||||
| Quartile 1 (≤ 1.16) | 49 / 705.81 | 1.00 | 1.00 | Referent | 26 / 371.09 | 1.00 | 1.00 | Referent |
| Quartile 2 (1.16 – 1.45) | 47 / 777.76 | 0.89 | 0.90 | (0.60, 1.36) | 24 / 245.88 | 1.24 | 1.09 | (0.58, 2.04) |
| Quartile 3 (1.46 – 1.76) | 45 / 875.76 | 0.74 | 0.73 | (0.47, 1.13) | 24 / 268.02 | 1.13 | 1.36 | (0.69, 2.68) |
| Quartile 4 (> 1.76) | 46 / 819.61 | 0.85 | 0.81 | (0.52, 1.26) | 25 / 308.30 | 1.03 | 1.10 | (0.61, 1.95) |
| p for trend | 0.252 | 0.647 | ||||||
| 9-cis RA | ||||||||
| Quartile 1 (≤ 0.96) | 49 / 799.84 | 1.00 | 1.00 | Referent | 24 / 339.91 | 1.00 | 1.00 | Referent |
| Quartile 2 (0.97 – 1.20) | 41 / 707.94 | 0.98 | 0.87 | (0.57, 1.34) | 26 / 281.30 | 1.20 | 1.49 | (0.77, 2.89) |
| Quartile 3 (1.21 – 1.48) | 50 / 879.51 | 1.02 | 0.91 | (0.60, 1.39) | 25/ 301.67 | 1.10 | 1.34 | (0.69, 2.59) |
| Quartile 4 (> 1.48) | 47 / 791.66 | 1.06 | 0.96 | (0.63, 1.46) | 24 / 270.42 | 1.15 | 1.80 | (0.91, 3.54) |
| p for trend | 0.866 | 0.148 | ||||||
| all-trans RA | ||||||||
| Quartile 1 (≤ 0.53) | 46 / 846.78 | 1.00 | 1.00 | Referent | 22 / 265.79 | 1.00 | 1.00 | Referent |
| Quartile 2 (0.54 – 0.71) | 47 / 780.85 | 1.09 | 1.25 | (0.81, 1.91) | 25 / 291.29 | 1.02 | 1.03 | (0.53, 1.99) |
| Quartile 3 (0.72 – 0.95) | 46 / 769.18 | 1.17 | 1.26 | (0.82, 1.93) | 26 / 360.54 | 0.98 | 1.32 | (0.71, 2.47) |
| Quartile 4 (> 0.95) | 48 / 782.13 | 1.26 | 1.22 | (0.79, 1.89) | 26 / 275.68 | 1.12 | 1.84 | (0.95, 3.59) |
| p for trend | 0.379 | 0.048 | ||||||
Numbers do not correspond to the crude measures since the Cox proportional hazard model accounts for the change in the RA over time while the numbers provided assume the HR does not vary over time.
Oncogenic models adjusted for income, education, pregnancy
Non-oncogenic models adjusted for age, marital status, pregnancy, number of lifetime partners, and age at first intercourse
Table 3.
Association between HPV-16 clearance and serum retinoic acid among 91-HPV 16 infections: Infection-level Analyses
| Nutrients (ng/mL) | No. Cleared /women- months* |
Crude | Adjusted† | ||
|---|---|---|---|---|---|
| HR | HR | (95% CI) | P-value | ||
| Total Retinoic Acid | |||||
| Quartile 1 & 2 (≤3.46) | 38 / 5.23.63 | 1.00 | 1.00 | Referent | |
| Quartile 3 & 4 (>3.46) | 28 / 564.01 | 0.69 | 0.58 | (0.35, 0.98) | 0.04 |
| 13-cis RA | |||||
| Quartile 1 & 2 (≤1.46) | 38 / 522.94 | 1.00 | 1.00 | Referent | |
| Quartile 3 & 4 (>1.46) | 28 / 564.70 | 0.68 | 0.67 | (0.41, 1.10) | 0.11 |
| 9-cis RA | |||||
| Quartile 1 & 2 (≤1.20) | 33 / 447.44 | 1.00 | 1.00 | Referent | |
| Quartile 3 & 4 (>1.20) | 33 / 640.20 | 0.75 | .63 | (0.38, 1.06) | 0.08 |
| all-trans RA | |||||
| Quartile 1 & 2 (≤ 0.71) | 35 / 581.26 | 1.00 | 1.00 | Referent | |
| Quartile 3 & 4 (< 0.71) | 31 / 506.38 | 1.08 | 1.07 | (0.60, 1.89) | 0.82 |
Numbers do not correspond to the crude measures since the Cox proportional hazard model accounts for the change in the RA over time while the numbers provided assume the HR does not vary over time.
HPV-16 models adjusted for age, income, pregnancy and age at first sexual intercourse.
Table 4 presents the relative risk of incident SIL according to endogenous RA isomer levels controlling for HPV status. The risk of incident SIL was not significantly associated with serum RA isomer level. Results did not differ when analyses were restricted to HPV positive cases (n=75) and controls (n=277) (data not shown). To further explore the relationship between endogenous RA and incident SIL, we conducted separate analyses for lesions that occurred within 2-years of RA measurement (n=46) and those that occurred ≥2- years after RA measurement (n=32). Risk estimates did not differ between these two approaches (data not shown).
Table 4.
Association between serum retinoic acid concentrations and incident squamous intraepithelial lesion (SIL) diagnosis.
| SIL status, no. | Odds Ratio | ||||
|---|---|---|---|---|---|
| Nutrient | Case | Control | Crude* | Adjusted† | (95% CI) |
| Total Retinoic Acid | |||||
| Quartile 1 (≤ 2.86) | 133 | 18 | 1.00 | 1.00 | Referent |
| Quartile 2 (2.86 – 3.46) | 140 | 21 | 1.32 | 1.24 | ( 0.59, 2.60) |
| Quartile 3 (3.47 – 4.11) | 136 | 17 | 0.93 | 0.79 | (0.36, 1.72) |
| Quartile 4 (> 4.11) | 137 | 21 | 1.32 | 1.23 | (0.57, 2.66) |
| p for trend | 0.89 | ||||
| 13-cis RA | |||||
| Quartile 1 (≤ 1.16) | 135 | 16 | 1.00 | 1.00 | Referent |
| Quartile 2 (1.16 – 1.45) | 137 | 15 | 0.89 | 0.77 | (0.34, 1.72) |
| Quartile 3 (1.46 – 1.76) | 137 | 21 | 1.37 | 1.12 | (0.52, 2.39) |
| Quartile 4 (> 1.76) | 137 | 25 | 1.72 | 1.44 | (0.68, 3.05) |
| p for trend | 0.19 | ||||
| 9-cis RA | |||||
| Quartile 1 (≤ 0.96) | 139 | 22 | 1.00 | 1.00 | Referent |
| Quartile 2 (0.97 – 1.20) | 134 | 14 | 0.78 | 0.86 | (0.40, 1.86) |
| Quartile 3 (1.21 – 1.48) | 133 | 16 | 0.87 | 0.87 | (0.41, 1.88) |
| Quartile 4 (> 1.48) | 140 | 25 | 1.34 | 1.51 | (0.75, 3.05) |
| p for trend | 0.27 | ||||
| all-trans RA | |||||
| Quartile 1 (≤ 0.53) | 139 | 27 | 1.00 | 1.00 | Referent |
| Quartile 2 (0.54 – 0.71) | 134 | 17 | 0.70 | 0.80 | (0.39, 1.63) |
| Quartile 3 (0.72 – 0.95) | 138 | 14 | 0.59 | 0.61 | (0.28, 1.30) |
| Quartile 4 (> 0.95) | 135 | 19 | 0.71 | 0.82 | (0.40, 1.68) |
| p for trend | 0.45 | ||||
Adjusted for HPV
Adjusted for HPV, income, pregnancy and age at first sexual intercourse
DISCUSSION
There were no consistently significant associations between serum RA isomers and oncogenic or non-oncogenic HPV clearance observed in this study. However increasing all-trans-RA was marginally associated with increased rate of non-oncogenic HPV clearance (p-trend=0.05). In addition, serum RA levels were not associated with risk of SIL. Based on these findings and results from completed trials of RA, we conclude that there is no association between RA and duration of an HPV infection or SIL detection.
Findings of a lack of association between serum RA isomers and HPV clearance and incident SIL are consistent with previous reports. Observational studies have suggested that precursors of RA (vitamin A and pro-vitamin A carotenoids) (15) were inversely associated with HPV persistence (24, 34), cervical dysplasia (35–37) and invasive cervical cancer (36, 38). However, epidemiologic findings have been inconsistent and several reports find no association between vitamin A or carotenoids and HPV persistence (25) or CIN. Of the five placebo controlled chemoprevention trials published (16–18, 20, 21), only one reported a significant reduction of CIN after treatment with all-trans-RA (16). A recent Cochrane review concluded there was no evidence of an effect of retinoids on regression of CIN III and only a possible, but statistically insignificant, effect on regression of CIN II(39). In a re-analysis of one trial (16), all-trans-RA treatment was marginally associated with regression of CIN II (OR=0.5; 95% CI 0.25–1.02; p=0.06)(39). Only one study has evaluated the association between serum all-trans-RA level and cervical lesions. Belin Grace and colleagues, who reported higher levels of all-trans-RA than found in our study, observed a significant inverse relationship between all-trans-RA and increasing cervical lesion severity (22).
The Ludwig-McGill Cohort Study offered a unique opportunity to assess the association between endogenous RA levels and HPV clearance/SIL lesion development in a sample of 634 women. This large well-characterized cohort had up to nine years of follow-up for the measurements of type-specific HPV infection and diagnosis of SIL lesions. The primary definition of HPV clearance included both prevalent and incident HPV infections; however, the conclusions did not change when analyses were restricted to incident infections. We applied a stringent definition of clearance (two consecutively negative HPV tests) to reduce misclassification and considered both the woman and the virus as the statistical unit of analysis. Due to the fact that the outcome ascertainment was based on cytologic analysis, a potential limitation of this study is misclassification of lesion outcome. However, all cytologic assessments were carefully conducted in a reference laboratory following a strict quality-control protocol. The Ludwig-McGill cohort opted for an intensive, expert cytologic review of all subjects in the study every 4–6 months and referred all instances of HSIL for colposcopy. This approach reduced the likelihood of unnecessary biopsies, which may interfere with the natural history of early lesions (40). Nevertheless, the occurrence of false-negative Pap tests could have resulted in under-estimates (or shorter estimates) of regression time and in either overestimates or underestimates of progression time; depending on whether these test results occurred at lesion outset of during the sojourn period.
A possible limitation of this study is the misclassification of circulating RA, either due to degradation over time or to intra-individual variability. As previously reported, circulating RA levels measured in this population are similar to previous studies and had low intra-individual variability(23). To further limit the misclassification of RA due to intra-individual variability, the current analyses utilized the mean of two measures from the same woman. Finally, we acknowledge that cervical RA levels may have a greater impact on the natural history of HPV compared to circulating levels.
While this is the largest study to evaluate the association between serum RA and HPV events, one may argue that our null findings may be due to a lack of statistical power to detect differences. For each RA isomer, we estimated the minimum mean difference in RA concentration detected between SIL cases and controls. Allowing for a 5% type I error rate, our study with 78 cases and 565 controls had 80% power to detect a mean difference in total RA of 0.32ng/ml, assuming a SD=0.96ng/ml for each group. This translates into a 9% difference, assuming a mean in the control group of 3.50ng/ml. Similarly, for each specific RA isomer measured, we had the statistical power to detect between a 10–13% difference by SIL group (data not shown). Overall, we had the statistical power to detect small percent differences in mean RA isomer level by case and control groups; if in fact differences did exist. The power estimates presented do not take into consideration possible misclassification of RA levels and may have overestimated the power of our study. It is possible that a much larger sample size might have found a statistical significant weak effect; however, the clinical significance of a significant weak effect is unclear.
Based on the consistency of a lack of an association between HPV and SIL with a sample size large enough to detect ≥9% difference in means, we conclude that there is no association between serum RA levels and HPV events. Our findings support results from chemoprevention trials that did not find an association between treatment with retinoic acid and regression of cervical dysplasia. In conclusion, the role of RA in inhibiting HPV induced carcinogenesis, as demonstrated in vitro, lacks confirmatory evidence within epidemiologic studies.
Supplementary Material
ACKNOWLEDGMENTS
We would like to acknowledge Dr. Ji-Hyun Lee for providing statistical expertise during manuscript preparation. We are indebted to Ms. Maria L. Baggio and Ms. Lenice Galan for management of the patients and specimen collections and to Ms. Silvaneide Ferreira and Ms. Raquel Hessel for data entry, sample retrieval and shipment and laboratory analysis.
Grant Support: National Cancer Institute (CA70269, CA81310), NCI Cancer Prevention and Control Pre-Doctoral Fellowship (R25CA078447), Canadian Institutes of Health Research (CIHR) (MA-13647, MOP-49396), and by an intramural grant by the Ludwig Institute for Cancer Research.
Footnotes
The authors of this manuscript do not have a commercial or other association that might pose a conflict of interest.
REFERENCES
- 1.Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–265. doi: 10.1136/jcp.55.4.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets. 2007;7:79–89. doi: 10.2174/156800907780006869. [DOI] [PubMed] [Google Scholar]
- 3.von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer. 2002;38:2229–2242. doi: 10.1016/s0959-8049(02)00462-8. [DOI] [PubMed] [Google Scholar]
- 4.Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition. 2000;16:1084–1089. doi: 10.1016/s0899-9007(00)00436-6. [DOI] [PubMed] [Google Scholar]
- 5.Abu J, Batuwangala M, Herbert K, Symonds P. Retinoic acid and retinoid receptors: potential chemopreventive and therapeutic role in cervical cancer. Lancet Oncol. 2005;6:712–720. doi: 10.1016/S1470-2045(05)70319-3. [DOI] [PubMed] [Google Scholar]
- 6.Ross AC, Zolfaghari R, Weisz J. Vitamin A: recent advances in the biotransformation, transport, and metabolism of retinoids. Curr Opin Gastroenterol. 2001;17:184–192. doi: 10.1097/00001574-200103000-00015. [DOI] [PubMed] [Google Scholar]
- 7.Napoli JL. Interactions of retinoid binding proteins and enzymes in retinoid metabolism. Biochim Biophys Acta. 1999;1440:139–162. doi: 10.1016/s1388-1981(99)00117-1. [DOI] [PubMed] [Google Scholar]
- 8.Heyman RA, Mangelsdorf DJ, Dyck JA, et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell. 1992;68:397–406. doi: 10.1016/0092-8674(92)90479-v. [DOI] [PubMed] [Google Scholar]
- 9.Blaner WS. Cellular metabolism and actions of 13-cis-retinoic acid. J Am Acad Dermatol. 2001;45:S129–S135. doi: 10.1067/mjd.2001.113714. [DOI] [PubMed] [Google Scholar]
- 10.Agarwal C, Rorke EA, Irwin JC, Eckert RL. Immortalization by human papillomavirus type 16 alters retinoid regulation of human ectocervical epithelial cell differentiation. Cancer Res. 1991;51:3982–3989. [PubMed] [Google Scholar]
- 11.Narayanan BA, Holladay EB, Nixon DW, Mauro CT. The effect of all-trans and 9-cis retinoic acid on the steady state level of HPV16 E6/E7 mRNA and cell cycle in cervical carcinoma cells. Life Sci. 1998;63:565–573. doi: 10.1016/s0024-3205(98)00307-5. [DOI] [PubMed] [Google Scholar]
- 12.Faluhelyi Z, Rodler I, Csejtey A, Tyring SK, Ember IA, Arany I. All-trans retinoic acid (ATRA) suppresses transcription of human papillomavirus type 16 (HPV16) in a dose-dependent manner. Anticancer Res. 2004;24:807–809. [PubMed] [Google Scholar]
- 13.Khan MA, Jenkins GR, Tolleson WH, Creek KE, Pirisi L. Retinoic acid inhibition of human papillomavirus type 16-mediated transformation of human keratinocytes. Cancer Res. 1993;53:905–909. [PubMed] [Google Scholar]
- 14.Creek KE, Jenkins GR, Khan MA, et al. Retinoic acid suppresses human papillomavirus type 16 (HPV16)-mediated transformation of human keratinocytes and inhibits the expression of the HPV16 oncogenes. Adv Exp Med Biol. 1994;354:19–35. doi: 10.1007/978-1-4899-0939-8_2. [DOI] [PubMed] [Google Scholar]
- 15.Giuliano AR. The role of nutrients in the prevention of cervical dysplasia and cancer. Nutrition. 2000;16:570–573. doi: 10.1016/s0899-9007(00)00338-5. [DOI] [PubMed] [Google Scholar]
- 16.Meyskens FL, Jr, Surwit E, Moon TE, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst. 1994;86:539–543. doi: 10.1093/jnci/86.7.539. [DOI] [PubMed] [Google Scholar]
- 17.Ruffin MT, Bailey JM, Normolle DP, et al. Low-dose topical delivery of all-trans retinoic acid for cervical intraepithelial neoplasia II and III. Cancer Epidemiol Biomarkers Prev. 2004;13:2148–2152. [PubMed] [Google Scholar]
- 18.Alvarez RD, Conner MG, Weiss H, et al. The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial. Cancer Epidemiol Biomarkers Prev. 2003;12:114–119. [PubMed] [Google Scholar]
- 19.Kim SH, Park TK, Kwon JY. 13-cis-retinoic acid for chemoprevention after colpoconization for cervical intraepithelial neoplasia. Int J Gynaecol Obstet. 2003;81:217–218. doi: 10.1016/s0020-7292(03)00032-8. [DOI] [PubMed] [Google Scholar]
- 20.Robinson WR, Andersen J, Darragh TM, Kendall MA, Clark R, Maiman M. Isotretinoin for low-grade cervical dysplasia in human immunodeficiency virus-infected women. Obstet Gynecol. 2002;99:777–784. doi: 10.1016/s0029-7844(02)01949-x. [DOI] [PubMed] [Google Scholar]
- 21.Follen M, Atkinson EN, Schottenfeld D, et al. A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin Cancer Res. 2001;7:3356–3365. [PubMed] [Google Scholar]
- 22.Berlin Grace VM, Niranjali Devaraj S, Radhakrishnan Pillai M, Devaraj H. HPV-induced carcinogenesis of the uterine cervix is associated with reduced serum ATRA level. Gynecol Oncol. 2006;103:113–119. doi: 10.1016/j.ygyno.2006.01.057. [DOI] [PubMed] [Google Scholar]
- 23.Siegel EM, Craft NE, Roe DJ, et al. Temporal variation and identification of factors associated with endogenous retinoic acid isomers in serum from Brazilian women. Cancer Epidemiol Biomarkers Prev. 2004;13:1693–1703. [PubMed] [Google Scholar]
- 24.Giuliano AR, Siegel EM, Roe DJ, et al. Dietary Intake and Risk of Persistent Human Papillomavirus (HPV) Infection: The Ludwig-McGill HPV Natural History Study. J Infect Dis. 2003;188:1508–1516. doi: 10.1086/379197. [DOI] [PubMed] [Google Scholar]
- 25.Siegel EM, Craft NE, Duarte-Franco E, Villa LL, Franco EL, Giuliano AR. Associations between serum carotenoids and tocopherols and type-specific HPV persistence: the Ludwig-McGill cohort study. Int J Cancer. 2007;120:672–680. doi: 10.1002/ijc.22346. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Franco E, Villa L, Rohan T, Ferenczy A, Petzl-Erler M, Matlashewski G Ludwig-McGill Study Group. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Rev Panam Salud Publica. 1999;6:223–233. doi: 10.1590/s1020-49891999000900001. [DOI] [PubMed] [Google Scholar]
- 27.Acta Cytol. Vol. 33. Bethesda, Maryland, U.S.A: Developed and approved at the National Cancer Institute Workshop; 1989. Dec 12–13, The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnoses; pp. 567–574. 1988. [PubMed] [Google Scholar]
- 28.Resnick RM, Cornelissen MT, Wright DK, et al. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst. 1990;82:1477–1484. doi: 10.1093/jnci/82.18.1477. [DOI] [PubMed] [Google Scholar]
- 29.Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. Jama. 1991;265:472–477. [PubMed] [Google Scholar]
- 30.Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol. 1998;36:3020–3027. doi: 10.1128/jcm.36.10.3020-3027.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Bernard HU, Chan SY, Manos MM, et al. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis. 1994;170:1077–1085. doi: 10.1093/infdis/170.5.1077. [DOI] [PubMed] [Google Scholar]
- 32.Horst RL, Reinhardt TA, Goff JP, et al. Identification of 9-cis,13-cis-retinoic acid as a major circulating retinoid in plasma. Biochemistry. 1995;34:1203–1209. doi: 10.1021/bi00004a013. [DOI] [PubMed] [Google Scholar]
- 33.Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007;90:1–636. [PMC free article] [PubMed] [Google Scholar]
- 34.Sedjo RL, Roe DJ, Abrahamsen M, et al. Vitamin A, carotenoids, and risk of persistent oncogenic human papillomavirus infection. Cancer Epidemiol Biomarkers Prev. 2002;11:876–884. [PubMed] [Google Scholar]
- 35.Goodman MT, Kiviat N, McDuffie K, et al. The association of plasma micronutrients with the risk of cervical dysplasia in Hawaii. Cancer Epidemiol Biomarkers Prev. 1998;7:537–544. [PubMed] [Google Scholar]
- 36.Palan PR, Mikhail MS, Goldberg GL, Basu J, Runowicz CD, Romney SL. Plasma levels of beta-carotene, lycopene, canthaxanthin, retinol, and alpha- and tautocopherol in cervical intraepithelial neoplasia and cancer. Clin Cancer Res. 1996;2:181–185. [PubMed] [Google Scholar]
- 37.Kwasniewska A, Tukendorf A, Semczuk M. Content of beta-carotene in blood serum of human papillomavirus infected women with cervical dysplasias. Arch Immunol Ther Exp (Warsz) 1996;44:309–313. [PubMed] [Google Scholar]
- 38.Potischman N, Hoover RN, Brinton LA, et al. The relations between cervical cancer and serological markers of nutritional status. Nutr Cancer. 1994;21:193–201. doi: 10.1080/01635589409514318. [DOI] [PubMed] [Google Scholar]
- 39.Helm CW, Lorenz DJ, Meyer NJ, Rising WR, Wulff JL. Retinoids for preventing the progression of cervical intra-epithelial neoplasia. Cochrane Database Syst Rev. 2007 doi: 10.1002/14651858.CD003296.pub2. CD003296. [DOI] [PubMed] [Google Scholar]
- 40.Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293–299. doi: 10.1093/jnci/93.4.293. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.